

Date – April 09, 2026

To, <b>BSE Limited (“BSE”),</b> Corporate Relationship Department, 2 <sup>nd</sup> Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400001	To, <b>National Stock Exchange of India Limited (“NSE”),</b> “Exchange Plaza”, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400051
<b>BSE Scrip code: 543399</b>	<b>NSE Symbol: TARSONS</b>

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

This is, in furtherance of the earlier intimation made on February 06, 2026 informing the Stock Exchanges about the decision of the Board of Directors of Tarsons Products Limited (“**the Company**”) for the further equity infusion of EUR 3,000,000 (Three Million Euros Only) in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., Singapore.

In continuation of the above and in compliance with Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform you that the Company has completed the equity investment amounting to EUR 300,000 (Three Hundred Thousand Euros Only), in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., incorporated in Singapore. Pursuant to the said investment, the Company has subscribed to 100 equity shares at a nominal value of EUR 3,000 per share. The aforesaid investment will be utilized towards quarterly repayment of the loan taken from the Bank in Singapore, interest payable thereon and meeting general corporate purposes and other operational and financial expenses.

The Company will further inform the stock exchanges as and when further tranches of equity investments are made.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith as **Annexure-A**.

This is for your information and records.

Thanking you,

**Yours Faithfully,**  
**For Tarsons Products Limited**

**Santosh Kumar Agarwal**  
**CFO, Company Secretary and Compliance Officer**  
**ICSI Membership No. A44836**

*Encl: As mentioned above*

Annexure-A

**Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:**

Sr. No.	Particulars	Details
1.	Name of the Target Entity, details in brief such as size, turnover, etc.:	<p>Tarsons Life Science Pte. Ltd. (“Target Entity”)</p> <p>Tarsons Life Science Pte. Ltd. is a wholly-owned subsidiary of Tarsons Products Limited (“the Company”) incorporated in Singapore.</p> <p>The Turnover of the Target Entity for the F.Y. 2025-26 is Nil.</p>
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:</p>	<p>Tarsons Life Science Pte. Ltd. being a wholly-owned subsidiary is a related party of the Company.</p> <p>The transaction falls within the ambit of a related party transaction and is at arm’s length basis.</p> <p>None of the Company’s promoter/ promoter group have any interest in the Target Entity other than through their shareholding in the Company.</p> <p>Further, Mr. Aryan Sehgal, Mr. Sanjive Sehgal and Mr. Subramanian Arun Kumar are the directors of the Company and also hold directorships in the Target Entity.</p>
3.	Industry to which the entity being acquired belongs:	<p>Tarsons Life Science Pte. Ltd. is engaged in the Non-Operating Financial Holding Companies.</p> <p>(The Target Entity is a Special Purpose Vehicle)</p>
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	<p>The additional capital infusion by the Company is to fund the needs of the target entity towards quarterly repayment of the loan taken from the Bank in Singapore, interest payable thereon and meeting general corporate purposes and other operational and financial expenses.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	Not Applicable
6.	Indicative time period for completion of the acquisition:	Completed.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same:	Cash consideration.

8.	Cost of acquisition and/or the price at which the shares are acquired:	Total consideration for the acquisition of 100 equity shares is EUR 300,000 (Three Hundred Thousand Euros Only), at a nominal value of EUR 3,000 per share.								
9.	Percentage of shareholding / control acquired and / or number of shares acquired:	<p>No change in ownership/percentage of shareholding.</p> <p>Tarsons Life Science Pte. Ltd. will continue to be a wholly-owned subsidiary of Tarsons Products Limited.</p> <p>Total number of shares allotted: 100 shares</p>								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Tarsons Life Science Pte. Ltd. is a wholly-owned subsidiary of Tarsons Products Limited.</p> <p>Date of incorporation: November 10, 2023.</p> <p>Country in which the acquired entity has presence: Singapore</p> <p>The turnover of Tarsons Life Science Pte. Ltd. since incorporation is as under:</p> <table border="1" data-bbox="846 911 1398 1146"> <thead> <tr> <th>Financial Year</th> <th>Amount in EUR</th> </tr> </thead> <tbody> <tr> <td>2025-26</td> <td>Nil</td> </tr> <tr> <td>2024-25</td> <td>Nil</td> </tr> <tr> <td>2023-24</td> <td>Nil</td> </tr> </tbody> </table> <p>Any other significant information: Nil</p>	Financial Year	Amount in EUR	2025-26	Nil	2024-25	Nil	2023-24	Nil
Financial Year	Amount in EUR									
2025-26	Nil									
2024-25	Nil									
2023-24	Nil									

For Tarsons Products Limited

Santosh Kumar Agarwal  
 CFO, Company Secretary and Compliance Officer  
 ICSI Membership No. A44836